Health Care • Medical/Dental Instruments
$1.43 ▲ +0.03
(+1.79%)
MKT CAP: $38.0M • VOL: 257.1K
52W L $1 52W H $11
ROARABLE / RQD
D- • 43/100
PIOTROSKI
5 / 9
CVRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $56.7M | $51.3M | $39.3M |
| YoY Revenue Growth % | +10.4% | +30.5% | — |
| Gross Profit | $48.3M | $43.0M | — |
| Gross Margin % | 85.3% | 83.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$51.3M | -$59.5M | -$43.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$53.3M | -$60.0M | -$41.2M |
| EBITDA (Normalized) | -$50.8M | -$58.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$40.2M | -$39.1M | -$39.0M |
| Capital Expenditures (CapEx) | $580.0K | $1.4M | — |
| Free Cash Flow (FCF) | -$40.8M | -$40.5M | -$39.0M |
| FCF Margin % | -71.9% | -79.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $75.7M | $105.9M | — |
| Total Debt (Short + Long Term) | $49.5M | $49.3M | — |
| Total Stockholders' Equity | $39.3M | $71.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CVRX.